Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2023-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine. In recent years, researchers at the Dana-Farber Cancer Institute have discovered that vaccines made from patient's own cancer cell, that have been engineered in the laboratory to produce a protein called GM-CSF, can be effective in stimulating a powerful immune response specific to that cancer. GM-CSF is a naturally occuring hormone in the body that helps our immune system fight infections and diseases. One of the goals of this study is to determine whether these vaccinations will improve the immune system's ability to recognize and destroy the participant's lymphoma cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

NCT00101101

Lymphoma

COMPLETED PHASE2

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

NCT02194751

Follicular Lymphoma

NOT_YET_RECRUITING PHASE2

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

NCT00258687

Sarcoma, Clear Cell Sarcoma, Alveolar Soft Part Renal Cell Carcinoma +1 more

COMPLETED PHASE1

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

NCT00080353

Melanoma

COMPLETED PHASE2

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893

Breast Neoplasms Metastases, Neoplasm

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The dose of vaccine will depend upon how many of the participant's own tumor cells are available and at which point they join study. This Phase I trial is a "dose escalation" study. This means that participants will be enrolled in groups. Group 2 will receive a larger dose than Group 1. Group 3 will receive a larger dose than Group 2.
* The vaccine is administered in injections under and into the skin six times. Participants will receive vaccination shots once weekly for 3 vaccines, then every other week for 3 vaccines.
* After the first and fifth vaccinations, a small amount of the participants own lymphoma cells (killed) will be injected under the skin to see if their immune system will react against it and cause redness and swelling. A punch skin biopsy will also be performed at these injection locations.
* During the course of the study, we will also be drawing blood to evaluate immune cells and the effect that the vaccinations have on the participants immune system. During all treatment cycles a physical exam and questions about the participants general health will be performed.
* After the final treatment (approximately week 10) the participant will undergo "re-staging" to assess the status of their disease. If after completion of six vaccines, evaluation of the participant's disease reveals that it is stable or responding to the vaccine, and there is still vaccine available, they may be eligible to continue to receive the vaccines every two weeks until their supply runs out.
* After completion of the vaccinations, participants will come back for physical exams and blood tests every 3 months for 1 year and then once a year for fifteen years to monitor the effects of the vaccine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Follicular Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biological/Vaccine

Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.

\--------------------------------------------------------------------------------

Group Type EXPERIMENTAL

Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells

Intervention Type BIOLOGICAL

Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells

Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed follicular lymphoma
* Patients with relapsed follicular lymphoma achieving at least a PR following their most recent systemic chemotherapy and/or immunotherapy regimen.
* Lymphoma accessible for sampling or existing cryopreserved lymphoma tumor judged suitable for vaccine preparation.
* 4 weeks must have elapsed between the completion of the the last chemotherapy, immunotherapy, glucocorticoid therapy, radiotherapy, or experimental therapy.
* ECOG Performance Status 0 or 1
* Estimated life expectancy of \> 6 months
* 35 years of age or older
* Adequate recovery of drug related toxicities, surgery or radiation therapy
* Greater than 6 months since autologous stem cell transplantation
* Laboratory parameters as outlined in the protocol

Exclusion Criteria

* Uncontrolled active infection or illness
* Psychiatric illness/social situation that would limit study compliance
* Pregnancy or nursing mothers
* Evidence of infection with HIV or viral hepatitis
* Other invasive malignancy
* Existing autoimmune cytopenia
* Previous allogeneic stem cell transplant
* Pre-existing autoimmune disease requiring anti-inflammatory therapy
* Participation in previous vaccine trial
* Any component of grade 3 follicular lymphoma or transformed follicular lymphoma

Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No